RESEARCH & DEVELOPMENT CENTER
KONZERN GROUP LTD.
Research & Development Center of Konzern Group Ltd. ("Group R&D Center") focuses on technology development and consultancy for the healthcare of mankind.
Primarily engaging in research and study of drugs, healthcare products, food and bioengineering, Group R&D Center is a comprehensive research institute of basic academic study, product development and technology upgrading. Currently, we have 50 R&D specialists in Group R&D Center and retain several well-known experts in the field of Pharmacy, Traditional Chinese Medicine ("TCM") and Pharmaceutical Technology home and abroad. We also form a strong alliance with domestic institutes and university of higher education to undertake the national (or provincial) key scientific projects and pipeline of our proprietary products. We are dedicating our efforts and resources to drug innovation, microbes study and healthcare products of natural plants and have accomplished some milestones as below:
Our New Drugs Research Institute ("NDRI") is located in Guangzhou LifeTech Pharmaceutical Co., Ltd., our wholly owned subsidiary. This institute is actively engaging in the R&D projects of innovative drugs related to oncology, cerebral-cardiovascular diseases and diabetes. Through the cooperation with Second Military Medical University, we successfully developed Glycididazole Sodium for Injection (CMNa), a patented intravenous injected medicine for the radiotherapy of solid tumors, which received the first rank new drug and manufacturing license from State Food and Drug Administration in 2002 and debut in the market in 2003. Recently, NDRI is undertaking the preclinical test of three new drugs and has completed the three-phase clinical trial of one new drug.
Led by Prof. Dongsheng Yao, Institute of Microbiao biotechnology of Jinan University (Co-win) ("IMB"), a research base formed by Guangzhou Co-win Bioengineering Co., Ltd. and Jinan University, primarily focus on the R&D of Aflatoxin B1-detoxification ("ADTZ") project. ADTZ is a new enzyme which can detoxify Aflatoxin B1 ("AFB1") in food and feed. So far ADTZ has received the patents granted by 21 countries and regions including China, the United States, the European Union, Australia, Canada, South Korea, Japan, Russia, etc.